腔内动脉瘤封堵术与腔内动脉瘤修复术的死亡率分析
本研究比较了EVAS-1试验中333例EVAS患者与VQI中16497例肾下EVAR对照者的5年全因死亡率,采用倾向评分加权和Cox回归分析。整体加权后两组5年死亡率相似(18% vs 14%;HR 1.1;95%CI 0.71-1.7;P=0.70)。亚组分析显示,动脉瘤直径<5.5 cm者EVAS死亡率更高(19% vs 11%;HR 2.4;95%CI 1.7-4.7;P=0.013);≥5.5 cm者EVAS前2年死亡率更低(HR 0.29;95%CI 0.13-0.62;P=0.002),但2-5年更高(HR 1.9;95%CI 1.2-3.0;P=0.005),5年时无差异(18% vs 17%;HR 0.82;95%CI 0.4-1.4;P=0.46)。
要点
- 整体加权后EVAS与EVAR的5年死亡率相似(18% vs 14%;HR 1.1;95%CI 0.71-1.7;P=0.70)。
- 动脉瘤直径<5.5 cm者EVAS的5年死亡率高于EVAR(19% vs 11%;HR 2.4;95%CI 1.7-4.7;P=0.013)。
- 动脉瘤直径≥5.5 cm者EVAS前2年死亡率更低(HR 0.29;95%CI 0.13-0.62;P=0.002),但2-5年更高(HR 1.9;95%CI 1.2-3.0;P=0.005)。
核心结论
- 在整体人群中,EVAS与EVAR的5年死亡率相似。
- 对于小动脉瘤(<5.5 cm)患者,EVAS与更高的死亡率相关。
- 对于较大动脉瘤(≥5.5 cm)患者,EVAS最初2年死亡率更低,但此后该优势消失,2年后死亡率更高。
研究设计与样本
- 比较EVAS-1 Nellix美国研究性器械豁免试验中333例EVAS患者与VQI中16497例肾下EVAR对照者(2014-2016年治疗),应用试验排除标准(血液透析、肌酐>2.0 mg/dL、破裂)。
- 次要分析按动脉瘤直径(<5.5 cm和≥5.5 cm)分层。
- 调整人口学、合并症和解剖特征后计算倾向评分,并应用逆概率加权,使用Kaplan-Meier和Cox回归分析比较风险调整后的长期死亡率。
主要发现
- 加权后,EVAS组与VQI对照组的5年死亡率相似(EVAS vs EVAR,18% vs 14%;HR 1.1;95%CI 0.71-1.7;P=0.70)。
- 动脉瘤直径<5.5 cm者,EVAS的5年死亡率高于EVAR(19% vs 11%;HR 2.4;95%CI 1.7-4.7;P=0.013)。
- 动脉瘤直径≥5.5 cm者,EVAS前2年死亡率更低(2年死亡率:HR 0.29;95%CI 0.13-0.62;P=0.002)。
- 动脉瘤直径≥5.5 cm者,EVAS在2-5年死亡率高于EVAR(HR 1.9;95%CI 1.2-3.0;P=0.005),5年时无死亡率差异(18% vs 17%;HR 0.82;95%CI 0.4-1.4;P=0.46)。
临床怎么用
- 作者认为,未来需要研究评估具体死亡原因,并阐明囊腔闭塞带来潜在初始生存获益的机制,以指导开发具有更好近端固定和封堵并整合囊腔闭塞的未来移植物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Endovascular aneurysm sealing (EVAS), using the Nellix endovascular aneurysm sealing system, has been associated with high reintervention and migration rates. However, prior reports have suggested that EVAS might be related to a lower all-cause mortality compared with endovascular aneurysm repair (EVAR). In the present study, we examined the 5-year all-cause mortality trends after EVAS and EVAR. METHODS: We compared the 333 EVAS patients in the EVAS-1 Nellix U.S. investigational device exemption trial with 16,497 infrarenal EVAR controls from the Vascular Quality Initiative, treated between 2014 and 2016, after applying the exclusion criteria from the investigational device exemption trial (ie, hemodialysis, creatinine >2.0 mg/dL, rupture). As a secondary analysis, we stratified the patients by aneurysm diameter (<5.5 cm and ≥5.5 cm). We calculated propensity scores after adjusting for demographics, comorbidities, and anatomic characteristics and applied inverse probability weighting to compare the risk-adjusted long-term mortality using Kaplan-Meier and Cox regression analyses. RESULTS: After weighting, the EVAS group had experienced similar 5-year mortality compared with the controls from the Vascular Quality Initiative (EVAS vs EVAR, 18% vs 14%; hazard ratio [HR], 1.1; 95% confidence interval [CI], 0.71-1.7; P = .70). The subgroup analysis demonstrated that for patients with an aneurysm diameter of <5.5 cm, EVAS was associated with higher 5-year mortality compared with EVAR (19% vs 11%; HR, 2.4; 95% CI, 1.7-4.7; P = .013). In patients with an aneurysm diameter of ≥5.5 cm, EVAS was associated with lower mortality within the first 2 years (2-year mortality: HR, 0.29; 95% CI, 0.13-0.62; P = .002). However, compared with EVAR, EVAS was associated with higher mortality between 2 and 5 years (HR, 1.9; 95% CI, 1.2-3.0; P = .005), with no mortality difference at 5 years (18% vs 17%; HR, 0.82; 95% CI, 0.4-1.4; P = .46). CONCLUSIONS: Within the overall population, EVAS was associated with similar 5-year mortality compared with EVAR. EVAS was associated with higher mortality for those with small aneurysms (<5.5 cm). For those with larger aneurysms (≥5.5 cm), EVAS was initially associated with lower mortality within the first 2 years, although this advantage was lost thereafter, with higher mortality after 2 years. Future studies are required to evaluate the specific causes of death and to elucidate the potential beneficial mechanism behind sac obliteration that leads to this potential initial survival benefit. This could help guide the development of future grafts with better proximal fixation and sealing that also incorporate sac obliteration.
引用
- Rastogi V, O'Donnell TFX, Solomon Y, et al. Mortality analysis of endovascular aneurysm sealing versus endovascular aneurysm repair. J Vasc Surg. 2022. PMID: 36651654. doi:10.1016/j.jvs.2022.10.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。